El Paso, TX (UPTICK Newswire – April 11, 2016) – Premier Biomedical, Inc. (OTCQB: BIEI) announced additional details regarding the presentation of the stunning results of their cancer immunotherapy research, along with additional research results by their UTEP scientist partners, at the upcoming American Association for Cancer Research (AACR) conference, April 16-20, 2016, in New Orleans. The presentation abstract can be found here.
William A. Hartman, President and CEO of Premier Biomedical, stated, “To have our research results accepted for presentation at such a prestigious conference as this, is a confirmation that our development of an effective anti-CTLA-4 cancer antibody (immunotherapy) is truly an exciting breakthrough! We are confident that our continuing research will result in effective cancer treatments for a number of cancer antigens.”
Contact William A. Hartman, President and CEO at (724) 633-7033, PR@premierbiomedical.com.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” http://www.premierbiomedical.com/
Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.